A carregar...
HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E
Redifferentiation therapy with BRAF/MEK inhibitors to facilitate treatment with radioiodine represents a good choice for radioiodine-refractory differentiated thyroid carcinoma, but recent initial clinical outcomes were modest. MAPK rebound caused by BRAF/MEK inhibitors-induced activation of HER2/HE...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5386727/ https://ncbi.nlm.nih.gov/pubmed/28423638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15773 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|